2-Methoxyjuglone
2-Methoxyjuglone, a naphthoquinone, is an apoptosis inducer. 2-Methoxyjuglone activates caspase-9 and caspase-3 via the mitochondrial cytochrome c-dependent intrinsic apoptosis cascade. 2-Methoxyjuglone increases pro-apoptotic Bax levels, decreases anti-apoptotic Bcl-2 levels, and promotes mitochondrial cytochrome c release. 2-Methoxyjuglone induces apoptosis morphological features, early apoptosis, S-phase and G2/M-phase cell cycle arrest, and DNA double-strand breaks. 2-Methoxyjuglone exerts activity against Gram-positive bacteria, pathogenic fungi, and phytopathogenic fungi. 2-Methoxyjuglone can be used for the research of hepatocellular carcinoma, osteosarcoma, colon adenocarcinoma, breast cancer, fungal infection, bacterial infection.
For research use only. We do not sell to patients.
- CAS No.: 15127-94-3
- Formula: C11H8O4
- Molecular Weight:204.18
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[2]|
Caspase 3 |
Caspase 9 |
Bax |
Bcl-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.08 μg/mL
Compound: 4
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 9599266] |
In Vitro
2-Methoxyjuglone (1.6-8.0 μg/mL; 24, 48, 72 h) reduces HepG2 human hepatocellular carcinoma cell viability in a dose- and time-dependent manner, with IC50 values of 3.8, 3.7, and 2.7 μg/mL after 24, 48, and 72 h of treatment, respectively[1].
2-Methoxyjuglone (4.8-8.0 μg/mL; 24 h) induces apoptotic morphological changes (cell shrinkage, membrane blebbing) in HepG2 human hepatocellular carcinoma cells[1].
2-Methoxyjuglone (1.6-8.0 μg/mL; 24, 48 h) induces S phase cell cycle arrest in HepG2 human hepatocellular carcinoma cells after 24 and 48 h of treatment at 1.6-8.0 μg/mL, and causes DNA fragmentation (sub-G1 phase accumulation) at 6.4 and 8.0 μg/mL after 48 h[1].
2-Methoxyjuglone (1.6-4.8 μg/mL; 24 h) induces HepG2 human hepatocellular carcinoma cell apoptosis via the mitochondrial cytochrome c-dependent intrinsic pathway, with dose-dependent increases in cytochrome c release, caspase-9 and caspase-3 activation, PARP cleavage, and Bax/Bcl-2 ratio after 24 h of treatment at 1.6-4.8 μg/mL[1].
2-Methoxyjuglone (10 μM; 1.25 μM, 24 h) potently inhibits DNA topoisomerase II at 10 μM and induces DNA double-strand breaks in human osteosarcoma U2OS cells at 1.25 μM, contributing to its cytotoxic activity[2].
2-Methoxyjuglone (62.5 μg/mL; 100 μM) exhibits potent in vitro antibacterial activity against multiple Gram-positive bacterial strains, with 100% growth inhibition of Bacillus subtilis at 100 μM, strong activity against Bacillus subtilis at 62.5 μg/mL[2].
2-Methoxyjuglone (0.25%-4%; 250 μg/mL; 8 μg/mL; 0.1-0.5 mg/mL) exhibits broad-spectrum in vitro antifungal activity against pathogenic and phytopathogenic fungi, with 100% inhibition of Fusarium graminearum spore germination at 0.5 mg/mL[2].
2-Methoxyjuglone potently inhibits the viability of human colon carcinoma HT-29 cells (IC50 = 2.6 μg/mL) and human breast carcinoma MCF-7 cells (IC50 = 1.2 μg/mL)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 human hepatocellular carcinoma cells
-
Concentration:1.6, 3.2, 4.8, 6.4, 8.0 μg/mL
-
Incubation Time:24, 48, 72 h
-
Result:Induced dose-dependent and time-dependent decreases in cell viability.
Reached IC50 values of 3.8 μg/mL (24 h), 3.7 μg/mL (48 h), and 2.7 μg/mL (72 h).
-
Cell Line:HepG2 human hepatocellular carcinoma cells
-
Concentration:4.8, 8.0 μg/mL
-
Incubation Time:24 h
-
Result:Caused cell shrinkage and membrane blebbing at 4.8 μg/mL.
Induced almost all cells to shrink with no normal morphological features at 8.0 μg/mL.\nReduced the number of cells on coverslips significantly and induced nuclear condensation with yellow staining (early apoptosis) at 4.8 μg/mL.
Caused almost all cells to detach from coverslips, with orange staining and apoptotic body formation (late apoptosis) at 8.0 μg/mL.
-
Cell Line:HepG2 human hepatocellular carcinoma cells
-
Concentration:1.6, 3.2, 4.8, 6.4, 8.0 μg/mL
-
Incubation Time:24, 48 h
-
Result:Increased the fraction of cells in the S phase (62%, 64%, 62%, 61%, 59% at 1.6, 3.2, 4.8, 6.4, 8.0 μg/mL, respectively) and decreased fractions in G1 and G2/M phases after 24 h.
Increased the fraction of cells in the S phase (49%, 64%, 66%, 52%, 46% at 1.6, 3.2, 4.8, 6.4, 8.0 μg/mL, respectively) after 48 h.
Induced dramatic increases in sub-G1 phase fraction (18% and 33%, respectively) at 6.4 and 8.0 μg/mL for 48 h, indicating DNA fragmentation associated with apoptosis.
-
Cell Line:HepG2 human hepatocellular carcinoma cells
-
Concentration:1.6, 3.2, 4.8 μg/mL
-
Incubation Time:24 h
-
Result:Increased cytoplasmic cytochrome c levels in a dose-dependent manner.
Activated caspase-9 via proteolytic cleavage of the 47 kDa pro-enzyme to the 35 kDa active form, increasing the cleaved/uncleaved ratio.
Activated caspase-3 via proteolytic cleavage of the 35 kDa pro-enzyme to the 17 kDa active form, increasing the cleaved/uncleaved ratio.
Increased the cleaved/uncleaved PARP ratio.
Elevated pro-apoptotic Bax protein levels and reduced anti-apoptotic Bcl-2 protein levels in a dose-dependent manner, resulting in an elevated Bax/Bcl-2 ratio.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming mice (male, SPF, 6 weeks old, 18-22 g, subcutaneous inoculation of H22 hepatocellular carcinoma cells)[1]
-
Dosage:0.25 mg/kg; 0.5 mg/kg; 1.0 mg/kg
-
Administration:i.p.; daily; 8 days
-
Result:Reduced tumor mass in mice.
Did not reduce the normal weight (total weight minus tumor weight) of mice at any tested dose.
Chemical Information
-
CAS No. 15127-94-3
-
Molecular Weight 204.18
-
Formula C11H8O4
-
SMILES
O=C1C=C(C(C2=C1C(O)=CC=C2)=O)OC
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
[1]. Yu HY, et al. 2-methoxyjuglone induces apoptosis in HepG2 human hepatocellular carcinoma cells and exhibits in vivo antitumor activity in a H22 mouse hepatocellular carcinoma model. J Nat Prod. 2013;76(5):889-895. [Content Brief]
[2]. Yu HY, et al. 2-Methoxyjuglone, a Promising Bioactive Compound for Pharmaceutical and Agricultural Purposes: A Review. Curr Med Sci. 2022;42(5):905-912. [Content Brief]
[3]. Li G, et al. DNA topoisomerases I and II inhibitory activity of constituents isolated from Juglans mandshurica. Arch Pharm Res. 2003;26(6):466-470. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)